

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 25, 2003.

*Francene Sawyer*  
Francene Sawyer

November 25, 2003  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appln. No.** : 10/632,187  
**Applicant** : Jürgen Engel et al.  
**Filed** : July 30, 2003  
**Title** : USE OF ALKYLPHOSPHOCHOLINES IN COMBINATION WITH  
ANTITUMOR MEDICATIONS FOR THE TREATMENT OF BENIGN  
AND MALIGNANT ONCOSES IN HUMANS AND MAMMALS  
**TC/A.U.** : 1615  
**Examiner** : TBA  
**Docket No.** : 103832-477-NP

Mail Stop Information Disclosure Statement  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Enclosed for filing in the above-identified application are the following items:

1. Information Disclosure Statement (2 copies);
2. PTO/SB/08A (Substitute 1449 Form) (2 copies);
3. Copies of the ten (10) documents listed on IDS; and
4. Return Receipt Postcard.

Respectfully submitted,

Dated: November 25, 2003


*Ann-Marie Koss*  
Ann-Marie Koss (Reg. No. 54,237)  
GOODWIN PROCTER LLP  
599 Lexington Avenue  
New York, NY 10022  
212.459-7434

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 25, 2003.

*Francene Sawyer*  
Francene Sawyer

November 25, 2003  
Date



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appl. No.** : 10/632,187  
**Applicant** : Jürgen Engel et al.  
**Filed** : July 30, 2003  
**Title** : USE OF ALKYLPHOSPHOCHOLINES IN COMBINATION WITH  
ANTITUMOR MEDICATIONS FOR THE TREATMENT OF BENIGN  
AND MALIGNANT ONCOSES IN HUMANS AND MAMMALS

**TC/A.U.** : 1615  
**Examiner** : TBA

**Docket No.** : 103832-477-NP

Mail Stop IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO/SB/08 (substitute for form 1449/PTO). Copies of the listed documents are enclosed.


The information contained in this Information Disclosure Statement was cited in the International Search Report (ISR) a copy of which issued in the corresponding PCT

Application No. PCT/EP03/08346. A copy of the ISR is enclosed. Applicant respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form and returning a copy to Applicant.


This Information Disclosure Statement is being filed before the mailing of a first office action on the merits under 37 C.F.R. §1.97(b), and therefore no fee is necessary. However, the Commissioner is still authorized to charge any required fees to Goodwin Procter LLP Deposit Account 06-0923.

Dated: November 25, 2003

Respectfully submitted for Applicant,

A handwritten signature in black ink, appearing to read 'Ann-Marie Koss', is written over a horizontal line.

Ann-Marie Koss (Reg. No. 54,237)  
GOODWIN PROCTER LLP  
599 Lexington Avenue  
New York, NY 10022  
212.459-7434



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Sheet

1

of

2

**Complete if Known**

Application Number	10/632,187
--------------------	------------

Filing Date	July 30, 2003
-------------	---------------

First Named Inventor	Jurgen Engel et al.
----------------------	---------------------

Art Unit	1614
----------	------

Examiner Name	TBA
---------------	-----

Attorney Docket Number	103832-477-NP
------------------------	---------------

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	1	WO 00/33917	06-15-2000	Max-Delbruck-Centrum		
	2	WO 02/066019 A2	08-29-2002	Novartis AG		
	3	WO 03/05522 A1	07-10-2003	Pharmacia Italia Spa		

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/632,187
Filing Date	July 30, 2003
First Named Inventor	Jurgen Engel et al.
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	103832-477-NP

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	THILO SPRUB, GUNTHER BERNHARDT, HELMUT SCHOENENBERGER and JURGEN ENGEL, Antitumor activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models; J Cancer Res Clin Oncol (1993) 119:142-149 (XP-000905599)	
	5	P. HILGARD, J. STEKAR, T. KLENNER, G. NOSSNER, B. KUTSCHER, and J. ENGEL; Heterocyclic Alkylphospholipids With an Improved Therapeutic Range; Advances In Experimental Medicine and Biology, United States (1996), 157-164 (XP-002256712)	
	6	J. STEKAR, P. HILGARD and T. KLENNER; Opposite Effect of Miltefosine on the Antineoplastic Activity and Haematological Toxicity of Cyclophosphamide; Eur J Cancer, Vol. 31A, No. 3, pp. 372-374, 1995 (XP-002256713)	
	7	MILKA C. GEORGIEVA, SPIRO M. KONSTANTINOV, MARGARIT TOPASHKA-ANCHEVA, MARTIN R. BERGER; Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells; Cancer Letters 182 (2002) 163-174 (XP-002256714)	
	8	D BERKOVIC, EAM FLEER, J BREASS, J PFORTNER, E SCHLEYER and W HIDDENMANN; The influence of 1-B-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells; Leukemia (1997) 11, 2079-2086 (XP-002256715)	
	9	SHOJI M.; RAYNOR R.L.; FLEER E.A.; EIBL H.; VOGLER W.R.; KUO J.F.; Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells; Journal Article (Feb. 1991) Vol. 26, No. 2, 145-149 (XP-002256716)	
	10	Copy of International Search Report	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.